Open main menu
Home
Random
Recent changes
Special pages
Community portal
Preferences
About Wikipedia
Disclaimers
Incubator escapee wiki
Search
User menu
Talk
Dark mode
Contributions
Create account
Log in
Editing
Buspirone
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
==Medical uses== ===Anxiety=== Buspirone is used for the short-term and long-term treatment of [[anxiety disorder]]s or symptoms of anxiety.<ref name=DM>{{cite web|title=Buspirone HCL (buspirone hydrochloride) tablet [Watson Laboratories, Inc.]|work=DailyMed|publisher=Watson Laboratories, Inc.|date=July 2013|access-date=14 November 2013|url=http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a3fe0ccd-565f-4d0a-a7ba-2fad7a819358}}</ref><ref name=TGA>{{cite web|title=Buspar (buspirone hydrochloride) Tablets 5 mg & 10 mg PRODUCT INFORMATION|work=TGA eBusiness Services|publisher=Aspen Pharma Pty Ltd|date=January 2010|access-date=14 November 2013|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-03962-3|format=PDF}}</ref><ref name=AMH>{{cite book | title=Australian Medicines Handbook | year=2013 | publisher=The Australian Medicines Handbook Unit Trust | isbn=978-0-9805790-9-3 | edition=2013 | place=Adelaide | veditors=Rossi S }}</ref><ref name=EMC>{{cite web |title=Buspirone 10mg Tablets |work=electronic Medicines Compendium |publisher=Actavis UK Ltd |date=10 September 2012 |access-date=14 November 2013 |url=http://www.medicines.org.uk/emc/medicine/23859/SPC/Buspirone+10mg+Tablets/|archive-date=13 November 2013|archive-url=https://web.archive.org/web/20131113191142/http://www.medicines.org.uk/emc/medicine/23859/SPC/Buspirone+10mg+Tablets/|url-status=dead}}</ref><ref name=BNF>{{cite book | last1=Joint Formulary Committee | title=British National Formulary (BNF) | publisher=Pharmaceutical Press | pages=224 }}</ref> It is generally preferred over [[benzodiazepine]]s because it does not activate the receptors that make drugs like [[alprazolam]] addictive.<ref name=Wil2018/> Buspirone has no immediate [[anxiolytic]] effects, and hence has a delayed [[onset of action]]; its full clinical effectiveness may require 2β4 weeks to manifest itself.<ref name="SadockSadock2014">{{cite book| vauthors=Sadock BJ, Sadock VA, Ruiz P |title=Kaplan and Sadock's Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry |url=https://books.google.com/books?id=IzGYBAAAQBAJ&pg=PT3211|date=22 September 2014|publisher=Wolters Kluwer Health |isbn=978-1-4698-8375-5|pages=3211β}}</ref> The drug is similarly effective in the treatment of [[generalized anxiety disorder]] (GAD) to benzodiazepines including [[diazepam]], alprazolam, [[lorazepam]], and [[clorazepate]].<ref name="pmid22608068" /> Buspirone is not known to be effective in the treatment of other anxiety disorders besides GAD.<ref name="pmid26535760">{{cite journal | vauthors=Howland RH | title=Buspirone: Back to the Future | journal=Journal of Psychosocial Nursing and Mental Health Services | volume=53 | issue=11 | pages=21β24 | date=November 2015 | pmid=26535760 | doi=10.3928/02793695-20151022-01 }}</ref> ===Other uses=== ====Sexual dysfunction==== There is some evidence that buspirone on its own may be useful in the treatment of [[hypoactive sexual desire disorder]] (HSDD) in women.<ref name="pmid27916394">{{cite journal |vauthors=Goldstein I, Kim NN, Clayton AH, DeRogatis LR, Giraldi A, Parish SJ, Pfaus J, Simon JA, Kingsberg SA, Meston C, Stahl SM, Wallen K, Worsley R |title=Hypoactive Sexual Desire Disorder: International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel Review |journal=Mayo Clinic Proceedings |volume=92 |issue=1 |pages=114β128 |date=January 2017 |pmid=27916394 |doi=10.1016/j.mayocp.2016.09.018 |doi-access=free }}</ref> Buspirone may also be effective in treating [[antidepressant]]-induced [[sexual dysfunction]].<ref name=Wil2018/><ref name="pmid34247952">{{cite journal |vauthors=Trinchieri M, Trinchieri M, Perletti G, Magri V, Stamatiou K, Cai T, Montanari E, Trinchieri A |title=Erectile and Ejaculatory Dysfunction Associated with Use of Psychotropic Drugs: A Systematic Review |journal=The Journal of Sexual Medicine |volume=18 |issue=8 |pages=1354β1363 |date=August 2021 |pmid=34247952 |doi=10.1016/j.jsxm.2021.05.016 |s2cid=235798526 |quote=Buspirone, a non-benzodiazepine anxiolytic, have even demonstrated enhancement of sexual function in certain individuals. For this reason, they have been proposed as augmentation agents (antidotes) or substitution agents in patients with emerging sexual dysfunction after treatment with antidepressants.}}</ref><ref name="pmid31591339">{{cite journal |vauthors=Montejo AL, Prieto N, de AlarcΓ³n R, Casado-Espada N, de la Iglesia J, Montejo L |title=Management Strategies for Antidepressant-Related Sexual Dysfunction: A Clinical Approach |journal=Journal of Clinical Medicine |volume=8 |issue=10 |date=October 2019 |page=1640 |pmid=31591339 |pmc=6832699 |doi=10.3390/jcm8101640 |doi-access=free }}</ref> ====Miscellaneous==== Buspirone is not effective as a treatment for [[benzodiazepine withdrawal syndrome|benzodiazepine withdrawal]], [[barbiturate withdrawal]], or [[alcohol withdrawal]].<ref>{{cite journal | vauthors=Sontheimer DL, Ables AZ | title=Is imipramine or buspirone treatment effective in patients wishing to discontinue long-term benzodiazepine use? | journal=The Journal of Family Practice | volume=50 | issue=3 | pages=203 | date=March 2001 | pmid=11252203 }}</ref> [[SSRI]] and [[SNRI]] antidepressants such as [[paroxetine]] and [[venlafaxine]], respectively, may cause jaw pain/jaw spasm reversible syndrome, although it is not common, and buspirone appears to be successful in treating antidepressant-induced [[bruxism]].<ref>{{cite journal | vauthors=Garrett AR, Hawley JS | title=SSRI-associated bruxism: A systematic review of published case reports | journal=Neurology. Clinical Practice | volume=8 | issue=2 | pages=135β141 | date=April 2018 | pmid=29708207 | pmc=5914744 | doi=10.1212/CPJ.0000000000000433 }}</ref><ref>{{cite journal| vauthors=Prisco V, Iannaccone T, Di Grezia G |date=1 April 2017 |title=Use of buspirone in selective serotonin reuptake inhibitor-induced sleep bruxism|journal=European Psychiatry|series=Abstract of the 25th European Congress of Psychiatry|volume=41 |pages=S855 |doi=10.1016/j.eurpsy.2017.01.1701 |s2cid=148816505 }}</ref>
Edit summary
(Briefly describe your changes)
By publishing changes, you agree to the
Terms of Use
, and you irrevocably agree to release your contribution under the
CC BY-SA 4.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)